Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 1
2015 2
2016 3
2018 3
2019 5
2020 15
2021 12
2022 4
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C, Pinato DJ. Cortellini A, et al. Among authors: tanda et. Clin Cancer Res. 2023 Jul 14;29(14):2714-2724. doi: 10.1158/1078-0432.CCR-22-3116. Clin Cancer Res. 2023. PMID: 37125965
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA. Cortellini A, et al. Among authors: tanda et. J Immunother Cancer. 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361. J Immunother Cancer. 2020. PMID: 33154150 Free PMC article.
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A, Tanda ET, Croce E, Catalano F, Ceppi M, Bruzzone M, Cecchi F, Arecco L, Fraguglia M, Pronzato P, Genova C, Del Mastro L, Lambertini M, Spagnolo F. Boutros A, et al. Among authors: tanda et. Eur J Cancer. 2023 Jul;188:64-79. doi: 10.1016/j.ejca.2023.04.010. Epub 2023 Apr 24. Eur J Cancer. 2023. PMID: 37196485 Free article. Review.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. Cantini L, et al. Among authors: tanda et. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. J Natl Cancer Inst. 2023. PMID: 37042716 Free PMC article.
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
Tanda ET, d'Amato AL, Rossi G, Croce E, Boutros A, Cecchi F, Spagnolo F, Queirolo P. Tanda ET, et al. Front Oncol. 2021 Sep 23;11:739006. doi: 10.3389/fonc.2021.739006. eCollection 2021. Front Oncol. 2021. PMID: 34631574 Free PMC article. Review.
The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A, Croce E, Ferrari M, Gili R, Massaro G, Marconcini R, Arecco L, Tanda ET, Spagnolo F. Boutros A, et al. Among authors: tanda et. Crit Rev Oncol Hematol. 2024 Apr;196:104276. doi: 10.1016/j.critrevonc.2024.104276. Epub 2024 Jan 29. Crit Rev Oncol Hematol. 2024. PMID: 38295889 Free article. Review.
The adjuvant treatment revolution for high-risk melanoma patients.
Spagnolo F, Boutros A, Tanda E, Queirolo P. Spagnolo F, et al. Among authors: tanda e. Semin Cancer Biol. 2019 Dec;59:283-289. doi: 10.1016/j.semcancer.2019.08.024. Epub 2019 Aug 21. Semin Cancer Biol. 2019. PMID: 31445219 Review.
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.
Vanni I, Tanda ET, Dalmasso B, Pastorino L, Andreotti V, Bruno W, Boutros A, Spagnolo F, Ghiorzo P. Vanni I, et al. Among authors: tanda et. Front Mol Biosci. 2020 Jul 24;7:172. doi: 10.3389/fmolb.2020.00172. eCollection 2020. Front Mol Biosci. 2020. PMID: 32850962 Free PMC article. Review.
57 results